Login to Your Account

'RALLY' on Accelerated Approval?

Talon Files Marqibo NDA in ALL Indication

By Jennifer Boggs

Tuesday, July 19, 2011
Only days after Seattle Genetics Inc. earned unanimous backing from an advisory panel for its Adcetris (brentuximab vedotin) in two lymphoma indications based on single-arm studies, another company is testing the FDA's accelerated approval pathway.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription